1 |
Differences in Vitreous Protein Profiles in Patients With Proliferative Diabetic Retinopathy Before and After Ranibizumab Treatment |
|
|
| Xinping She, Chen Zou, Zhi Zheng |
|
| Frontiers in Medicine. 2022; 9 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
2 |
COMPARISON OF VISUAL ACUITY OUTCOME IN PROLIFERATIVE DIABETIC RETINOPATHY(PDR) BETWEEN INTRAVITREAL BEVACIZUMAB AND RANIBIZUMAB INJECTIONS |
|
|
| Kalishankar Das, Shafaque Sahar, Kesha Shah, Athokpam Poireiton |
|
| INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH. 2022; : 35 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
3 |
Current intravitreal therapy and ocular hypertension: A review |
|
|
| Aditya Sudhalkar, Alper Bilgic, Shail Vasavada, Laurent Kodjikian, Thibaud Mathis, FransescMarch de Ribot, Thanos Papakostas, Viraj Vasavada, Vaishali Vasavada, Samaresh Srivastava, Deepak Bhojwani, Pooja Ghia, Anand Sudhalkar |
|
| Indian Journal of Ophthalmology. 2021; 69(2): 236 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
4 |
The use of thalidomide to treat children with tuberculosis meningitis: A review |
|
|
| Ronald van Toorn, Stefan-Dan Zaharie, James A. Seddon, Martijn van der Kuip, A. Marceline van Furth, Johan F. Schoeman, Regan S. Solomons |
|
| Tuberculosis. 2021; 130: 102125 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
5 |
Sustained Intraocular Pressure Rise after the Treat and Extend Regimen at 3 Years: Aflibercept versus Ranibizumab |
|
|
| Alper Bilgic, Laurent Kodjikian, Jay Chhablani, Anand Sudhalkar, Megha Trivedi, Viraj Vasavada, Vaishali Vasavada, Shail Vasavada, Samaresh Srivastava, Deepak Bhojwani, Aditya Sudhalkar |
|
| Journal of Ophthalmology. 2020; 2020: 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
6 |
A review of anti-VEGF agents for proliferative diabetic retinopathy |
|
|
| P Osaadon,X J Fagan,T Lifshitz,J Levy |
|
| Eye. 2014; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
7 |
Microvascular complications and diabetic retinopathy: recent advances and future implications |
|
|
| Megha Barot,Mitan R Gokulgandhi,Sulabh Patel,Ashim K Mitra |
|
| Future Medicinal Chemistry. 2013; 5(3): 301 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
8 |
The pathogenesis of early retinal changes of diabetic retinopathy |
|
|
| G. B. Arden, S. Sivaprasad |
|
| Documenta Ophthalmologica. 2012; |
|
| [HTML Full text] [Google Scholar] [DOI] |
|
9 |
Treatment of proliferative diabetic retinopathy with anti-VEGF agents |
|
|
| Aysha Salam, Raeba Mathew, Sobha Sivaprasad |
|
| Acta Ophthalmologica. 2011; : no |
|
| [HTML Full text] [Google Scholar] [DOI] |
|
10 |
Review of Anti-VEGF Therapy in Proliferative Diabetic Retinopathy |
|
|
| Jardeleza, M.S.R. and Miller, J.W. |
|
| . 2009; 24(2): 87-92 |
|
| [Pubmed] [Google Scholar] |
|
11 |
Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study |
|
|
| Raquel Costa, Ângela Carneiro, Ana Rocha, Ana Pirraco, Manuel Falcão, Luísa Vasques, Raquel Soares |
|
| Journal of Cellular Biochemistry. 2009; 108(6): 1410-1417 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
12 |
Effects of hydralazine on ocular blood flow and laser-induced choroidal neovascularization |
|
|
| Jiang, W., Chiou, G.C.Y. |
|
| International Journal of Ophthalmology. 2008; 8(12): 2359-2363 |
|
| [Pubmed] [Google Scholar] |
|
13 |
New VEGF antagonists as possible therapeutic agents in vascular disease |
|
|
| Slevin, M., Kumar, P., Wang, Q., Kumar, S., Gaffney, J., Grau-Olivares, M., Krupinski, J. |
|
| Expert Opinion on Investigational Drugs. 2008; 17(9): 1301-1314 |
|
| [Pubmed] [Google Scholar] |
|
14 |
New VEGF antagonists as possible therapeutic agents in vascular disease |
|
|
| M Slevin,P Kumar,Quiyu Wang,S Kumar,J Gaffney,M Grau-Olivares,J Krupinski |
|
| Expert Opinion on Investigational Drugs. 2008; 17(9): 1301 |
|
| [Pubmed] [Google Scholar] [DOI] |
|